AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NYSEARCA:MORMORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Stock Price, Forecast & News

$32.18
+0.02 (+0.06 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$32.18
Now: $32.18
$32.78
50-Day Range
$24.47
MA: $28.04
$33.35
52-Week Range
$18.21
Now: $32.18
$37.96
Volume77,300 shs
Average Volume134,466 shs
Market Capitalization$4.23 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs; and a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys' investigational compound tafasitamab (MOR208). The company was founded in 1992 and is headquartered in Planegg, Germany.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEARCA:MOR
CUSIPN/A
CIKN/A
Phone49 89 89927 0

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees516
Market Cap$4.23 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) Frequently Asked Questions

How has MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's stock been impacted by COVID-19 (Coronavirus)?

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's stock was trading at $25.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MOR shares have increased by 27.4% and is now trading at $32.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500.

What guidance has MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 issued on next quarter's earnings?

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 issued an update on its FY 2020 After-Hours earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $308.84-319.87 million, compared to the consensus revenue estimate of $309.77 million.

Has MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 been receiving favorable news coverage?

News articles about MOR stock have trended very negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutMORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500.

Who are some of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's key competitors?

What other stocks do shareholders of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 investors own include AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Pfizer (PFE), Amplify Energy (AMPY), Amplify Energy (AMPY), Algonquin Power & Utilities (AQN), BCE (BCE), Franklin Resources (BEN) and Bank of Nova Scotia (BNS).

Who are MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's key executives?

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's management team includes the following people:
  • Dr. Jean-Paul Kress, Chairman of Management Board, MD & CEO (Age 55)
  • Mr. Jens H. Holstein, CFO & Member of the Management Board (Age 56)
  • Dr. Malte Peters M.D., Chief R&D Officer and Member of the Management Board (Age 58)
  • Mr. Roland Wandeler Ph.D., Chief Commercial Officer & Member of Management Board
  • Mr. Klaus De Wall, Head of Accounting & Tax

What is MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's stock symbol?

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "MOR."

How do I buy shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500?

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's stock price today?

One share of MOR stock can currently be purchased for approximately $32.18.

How big of a company is MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500?

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a market capitalization of $4.23 billion. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 employs 516 workers across the globe.

What is MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500's official website?

The official website for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 is www.morphosys.com.

How can I contact MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500?

The company can be reached via phone at 49 89 89927 0.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.